OTCMKTS:DGNOF DIAGNOS (DGNOF) Stock Price, News & Analysis $0.18 +0.00 (+2.68%) As of 04/25/2025 03:30 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock About DIAGNOS Stock (OTCMKTS:DGNOF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DIAGNOS alerts:Sign Up Key Stats Today's Range$0.18▼$0.1950-Day Range$0.17▼$0.2552-Week Range$0.17▼$0.31Volume75,900 shsAverage Volume69,461 shsMarket Capitalization$18.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewDIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More… Receive DGNOF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address DGNOF Stock News HeadlinesDIAGNOS announces major advances in Cybersecurity certification by the Cyber Defense Operations Center (COCD) for its CARA System applicationApril 16, 2025 | globenewswire.comDIAGNOS Provides Additional Information on Amendment to Convertible DebenturesApril 14, 2025 | globenewswire.comIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.April 26, 2025 | Porter & Company (Ad)DIAGNOS Provides Update on its Health Canada Medical Device Licence ApplicationApril 9, 2025 | globenewswire.comDIAGNOS Announces Amendment to Convertible DebenturesMarch 31, 2025 | globenewswire.comDIAGNOS is filing for the Saudi FDA Authorization of Its CARA SYSTEM, an AI Assisted Medical DeviceMarch 12, 2025 | globenewswire.comDIAGNOS Announces Amendment to Convertible DebenturesFebruary 28, 2025 | globenewswire.comDIAGNOS to File for FDA Pre-Market Authorization of Its AI-Powered CARA SYSTEM and Engages Ora as Regulatory SpecialistFebruary 25, 2025 | globenewswire.comSee More Headlines DGNOF Stock Analysis - Frequently Asked Questions How have DGNOF shares performed this year? DIAGNOS's stock was trading at $0.1950 at the beginning of the year. Since then, DGNOF shares have decreased by 5.7% and is now trading at $0.1838. View the best growth stocks for 2025 here. How were DIAGNOS's earnings last quarter? DIAGNOS Inc. (OTCMKTS:DGNOF) issued its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter. How do I buy shares of DIAGNOS? Shares of DGNOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/12/2025Today4/26/2025Next Earnings (Estimated)7/15/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorBusiness Services Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:DGNOF CIKN/A Webwww.diagnos.ca Phone(450) 678-8882FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,310,000.00 Net Margins-2,912.77% Pretax Margin-2,423.01% Return on EquityN/A Return on Assets-242.73% Debt Debt-to-Equity RatioN/A Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$130,000.00 Price / Sales144.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-6.13Miscellaneous Outstanding Shares101,863,000Free FloatN/AMarket Cap$18.72 million OptionableNot Optionable Beta0.23 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (OTCMKTS:DGNOF) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDeepSeek’s Clear and Present DangerDeepSeek — the alleged “$5.5 million” AI project — isn’t an open-source breakthrough. It’s a Trojan horse.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIAGNOS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.